Validea Detailed Fundamental Analysis

Validea's P/B Growth Investor model, based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained growth potential, rated Johnson & Johnson (JNJ) at 77%. This score, while strong, falls just below the 80% threshold typically indicating investor interest. JNJ passed most fundamental criteria for growth, but notably failed on specific metrics concerning cash flow efficiency relative to return on assets and research and development to assets.

Analysis

Johnson & Johnson (JNJ) received a 77% rating from Validea's P/B Growth Investor model, a quantitative strategy based on academic research by Partha Mohanram designed to identify low book-to-market stocks with potential for sustained growth. This score, while indicating fundamental strength, falls just below the 80% threshold that the model uses to signify notable interest. The analysis reveals that JNJ, a large-cap stock in the Biotechnology & Drugs industry, successfully passed most of the model's criteria, including Return on Assets, Sales Variance, and Capital Expenditures to Assets. However, the company failed on two specific metrics: the ratio of Cash Flow from Operations to Assets versus Return on Assets, and the level of Research and Development to Assets. This suggests a potential discrepancy between accounting profits and cash generation, and that its R&D investment may be considered suboptimal under this particular growth-focused framework, presenting a mixed but moderately positive fundamental picture.

Key Decisions for Investors

• Investors should note that while JNJ exhibits many positive fundamental traits, its 77% score in this specific growth model places it just below the threshold of high conviction, suggesting it may be more of a stable holding than a dynamic growth opportunity.
• Further due diligence is warranted on the two failed metrics; specifically, an examination of why cash flow from operations does not align perfectly with return on assets and whether the current R&D expenditure is sufficient to fuel long-term growth in the competitive drug industry.
• For portfolios strictly adhering to growth-at-a-reasonable-price (GARP) principles similar to the Mohanram model, JNJ's profile presents a cautionary signal, while value or income-focused investors might find the underlying stability, evidenced by passing most other criteria, more attractive.